Announcement • Mar 20
Pila Pharma AB (publ), Annual General Meeting, May 19, 2026 Pila Pharma AB (publ), Annual General Meeting, May 19, 2026, at 15:00 W. Europe Standard Time. Reported Earnings • Feb 11
Full year 2025 earnings released: kr0.49 loss per share (vs kr0.44 loss in FY 2024) Full year 2025 results: kr0.49 loss per share (further deteriorated from kr0.44 loss in FY 2024). Net loss: kr16.9m (loss widened 50% from FY 2024). Over the last 3 years on average, earnings per share has increased by 45% per year but the company’s share price has fallen by 24% per year, which means it is significantly lagging earnings. New Risk • Jan 17
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Swedish stocks, typically moving 8.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Shareholders have been substantially diluted in the past year (55% increase in shares outstanding). Revenue is less than US$1m (kr958k revenue, or US$104k). Market cap is less than US$10m (kr91.3m market cap, or US$9.90m). Minor Risk Share price has been volatile over the past 3 months (8.3% average weekly change). Announcement • Dec 23
Pila Pharma AB (publ) to Report First Half, 2026 Results on Aug 27, 2026 Pila Pharma AB (publ) announced that they will report first half, 2026 results on Aug 27, 2026 Announcement • Dec 20
Pila Pharma AB (publ) Initiates the Planned Preclinical Studies in Obesity Pila Pharma AB (publ) announced that it has initiated the planned preclinical studies in obesity. The aim is to demonstrate preclinical proof-of-concept of PILA PHARMA's proprietary clinical drug candidate XEN-D0501 in rats with obesity. During July, PILA PHARMA completed a rights issue of units to make "a bet on obesity" by demonstrating proof-of-concept in obesity. First in rats, and then in humans. Initially it was planned to use the same oral formulation that was successfully used in the 13-week tox study in normal rats, previously conducted by PILA PHARMA. However, it has been decided to use a formulation well known by Gubra to ensure the best fit to dosing obese rats. The readout of the rat studies are confirmed to be on track and results communicated prior to the TO2 warrant exercise period. The net proceeds from the warrants are intended to finance clinical trials of PILA PHARMA' clinical development candidate XEN-D051 in obesity. Announcement • Oct 29
Pila Pharma AB (publ) announced that it has received SEK 30 million in funding Pila Pharma AB (publ) announced private placement of common shares for gross proceeds of SEK 30,000,000 on October 28, 2025. The subscription rate was 293.5% meaning that investors have wanted to invest more than the company had initially offered. Announcement • Sep 04
Pila Pharma AB (publ) to Report Fiscal Year 2025 Final Results on Mar 19, 2026 Pila Pharma AB (publ) announced that they will report fiscal year 2025 final results on Mar 19, 2026 Reported Earnings • Aug 28
First half 2025 earnings released: kr0.15 loss per share (vs kr0.17 loss in 1H 2024) First half 2025 results: kr0.15 loss per share. Revenue: kr851.0k (up 25% from 1H 2024). Net loss: kr4.10m (flat on 1H 2024). New Risk • Jul 28
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 37% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr7.8m free cash flow). Share price has been highly volatile over the past 3 months (15% average weekly change). Shareholders have been substantially diluted in the past year (37% increase in shares outstanding). Revenue is less than US$1m (kr790k revenue, or US$82k). Minor Risk Market cap is less than US$100m (kr126.0m market cap, or US$13.1m). Reported Earnings • Feb 28
Full year 2024 earnings released Full year 2024 results: Revenue: kr790.0k (down 46% from FY 2023). Net loss: kr11.2m (loss widened 13% from FY 2023). Announcement • Dec 19
Pila Pharma AB (Publ) Announces Preclinical Preclinical Proof-Of-Concept Achieved in Cardiometabolic Diseases PILA PHARMA AB (publ) announced the completion of the study of the Research Group of Professor Dick Wagsater, Uppsala University, Sweden (the "Research Group"). The preliminary results showed that PILA PHARMA's lead candidate, the TRPV1 antagonist, XEN-D0501, significantly reduced Abdominal Aorta Aneurysm growth in mice. The aim of the preclinical study was to establish a pre-clinical proof-of-concept of that the TRPV1 antagonist XEN-D0501 could decrease Abdominal Aneurysm growth In mice. The headline study results show that XEN-D0501 had a robust decrease in aorta dilatation of more than 50% compared to placebo, which was the goal. It almost completely inhibited aneurysm development in this pre-clinical model, thus, establishing proof-of-concept. Pending a confirmatory study, the data will be published and presented in a scientific outlet. XEN-D0501 is a selective, synthetic potent small molecule TRPV1 antagonist that was in-licensed in 2016. TRPV1 antagonists that down-regulate neurogenic inflammation, has demonstrated applications across pain and inflammatory diseases and potentially plays a role in diabetes and potentially other metabolic disorders like obesity. Prior to in-licensing, XEN-D051 had been found to have a good safety profile in other (non-diabetic) patient groups. PILA PHARMA has to date completed two phase 2a clinical trials (PP-CT01 and PP-CT02), that both demonstrated that XEN-D051 is well tolerated by in people living with obesity and type 2 diabetes. Further, PP-CT02, demonstrated that XEN-D0701 (administered as 4 mg bidaily for 28 days) - with statistical significance versus placebo - enhanced the endogenous insulin response to oral glucose. Furthermore, ANP, a cardiovascular biomarker for heart failure, was highly statistically significantly reduced. During 2023 the Company could report very good tolerability of XEN-D0501 following 13 weeks administration of very high doses in 2 animal species, and XEN-D0501 can thus progress into longer clinical trials. Currently, a scientific advice regarding the study design of the next clinical phase 2a trial, PP-CT03, is being prepared and will be followed by a clinical trial submission in the UK. The objective of the study is to identify the maximal tolerable dose of XEN-D051 in people living with obesity and Type 2 diabetes and to evaluate the safety profile following 3 months chronic treatment. In addition to the safety assessment, PP-CT03 will also include sufficient participants that should allow for efficacy readouts on reduction of body weight. New Risk • Dec 02
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: kr107.2m (US$9.73m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr5.0m free cash flow). Share price has been highly volatile over the past 3 months (12% average weekly change). Revenue is less than US$1m (kr1.0m revenue, or US$95k). Market cap is less than US$10m (kr107.2m market cap, or US$9.73m). Minor Risk Shareholders have been diluted in the past year (47% increase in shares outstanding). Recent Insider Transactions • Nov 20
Founder recently bought kr100k worth of stock On the 14th of November, Dorte Gram bought around 20k shares on-market at roughly kr4.99 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Dorte's only on-market trade for the last 12 months. Announcement • Nov 14
PILA PHARMA AB (publ) Announces Selection of Clinical Trial Site and Decision to Seek Scientific Advice for Optimized PP-CT03 Study Design PILA PHARMA AB (publ) announced the selection of the principal investigator, Professor Mark Evans and Cambridge University Hospital as principal clinical trial site for the conduct of PP-CT03 as well as the as having decided to seek further scientific advice as first step. On 17 October, PILA PHARMA informed of optimization changes to the trial plan for PP-CT03 plan, due mainly to internal safety concerns of running the trial at a non-hospital site, as well as the decision to conduct at least the initial part at a hospital site. The company has now selected the scientific advisor to PILA PHARMA, Professor Mark Evans, as principal investigator of the study and the Cambridge University Hospital, UK, as the principal trial site of PP-CT03. Furthermore, following discussions with Professor Evans, it has been decided to seek scientific advice with the UK MRHA prior to clinical trial application. The objective is to further strengthen the PP-CT03 study design and increase the opportunity for this study to provide input to a clear development and regulatory plan in diabetes and potentially obesity. Reported Earnings • Aug 28
First half 2024 earnings released First half 2024 results: Revenue: kr683.0k (down 38% from 1H 2023). Net loss: kr4.09m (loss narrowed 42% from 1H 2023). Announcement • Apr 24
Pila Pharma AB (publ) to Report First Half, 2024 Results on Aug 27, 2024 Pila Pharma AB (publ) announced that they will report first half, 2024 results on Aug 27, 2024 Reported Earnings • Feb 29
Full year 2023 earnings released: kr0.54 loss per share (vs kr1.55 loss in FY 2022) Full year 2023 results: kr0.54 loss per share (improved from kr1.55 loss in FY 2022). Revenue: kr1.46m (down 22% from FY 2022). Net loss: kr9.93m (loss narrowed 63% from FY 2022). Announcement • Dec 06
Pila Pharma AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 8.07888 million. Pila Pharma AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 8.07888 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 5,385,920
Price\Range: SEK 1.5
Transaction Features: Rights Offering Reported Earnings • Oct 27
Third quarter 2023 earnings released Third quarter 2023 results: Net loss: kr1.53m (loss narrowed 74% from 3Q 2022). Reported Earnings • Aug 23
Second quarter 2023 earnings released Second quarter 2023 results: Revenue: kr301.0k (down 54% from 2Q 2022). Net loss: kr3.06m (loss narrowed 53% from 2Q 2022). Reported Earnings • Apr 27
First quarter 2023 earnings released: kr0.22 loss per share (vs kr0.64 loss in 1Q 2022) First quarter 2023 results: kr0.22 loss per share (improved from kr0.64 loss in 1Q 2022). Revenue: kr796.0k (up 49% from 1Q 2022). Net loss: kr4.04m (loss narrowed 61% from 1Q 2022). Recent Insider Transactions • Apr 06
Founder recently bought kr50k worth of stock On the 31st of March, Dorte Gram bought around 24k shares on-market at roughly kr2.10 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Dorte has been a buyer over the last 12 months, purchasing a net total of kr100k worth in shares. Board Change • Nov 16
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Director Milan Zdravkovic was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Board Change • Apr 27
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 1 highly experienced director. No independent directors (4 non-independent directors). Director Gudmund Korsgard was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. 
